xRead - September 2022

Wise et al.

Page 368

Author Manuscript Author Manuscript Author Manuscript Author Manuscript Study design Study groups Clinical endpoint Conclusion 3 Placebo

and superior to placebo at both doses.

8-item symptom score Azelastine twice-daily superior to placebo.

placebo for symptoms; no change in airway resistance with either treatment.

nasal symptoms and superior for ocular symptoms; both treatments superior to placebo.

Azelastine at least as effective as loratadine.

Azelastine at least as effective as budesonide for symptoms; flow rate improved in both treatment groups.

Comparable improvement in nasal symptoms, nPIFR, ESS and QOL; azelastine superior for ocular symptoms.

13-item symptom score Comparable symptom improvement.

11-item symptom score Azelastine comparable to chlorpheniramine

13-item symptom score Azelastine at least as effective as cetirizine.

TNSS, rhinomanometry Azelastine superior to beclomethasone and 12-item symptom score, global assessment 10-item symptom score, nasal flow rate

13-item symptom score Azelastine comparable to budesonide for TNSS, nPIFR, ESS, SF-36, mini-RQLQ

Gastpar et al. 1234 1994 1b DBRCT 1 Azelastine 0.28 mg daily;

2 Terfenadine 60-mg tablet daily Meltzer et al. 1235 1994 1b DBRCT 1 Azelastine 0.28 mg daily;

2 Azelastine 0.28 mg BID;

3 Chlorpheniramine 12-mg tablet BID; 4 Placebo

Passali & Piragine 1236 1994 1b DBRCT 1 Azelastine 0.28 mg BID;

2 Cetirizine 10-mg tablet daily

Ratner et al. 1237 1994 1b DBRCT 1 Azelastine 0.28 mg daily;

2 Azelastine 0.28 mg BID; 3 Placebo

Davies et al. 1238 1993 1b DBRCT 1 Azelastine 0.28 mg BID;

2 Beclomethasone dipropionate 0.1 mg spray BID; 3 Placebo

Dorow et al. 1239 1993 1b DBRCT 1 Azelastine 0.28 mg BID;

2 Budesonide 0.10 mg spray BID; 3 Placebo

Gambardella 1240 1993 1b DBRCT 1 Azelastine 0.28 mg BID;

2 Loratadine 10-mg tablet daily

Gastpar et al. 1241 1993 1b DBRCT 1 Azelastine 0.28 mg BID; blind RCT

2 Budesonide 0.10 mg spray BID 1 Azelastine 0.56 mg BID;

2 Triamcinolone acetonide 0.22 mg spray daily

Study Year LOE

Kalpaklioglu & Kavut 1203 2010 2b Single

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.